Pure Global
NCT01026493

Veliparib and Temozolomide in Treating Patients With Recurrent Glioblastoma

A Randomized Phase I/II Study of ABT-888 in Combination With Temozolomide in Recurrent (Temozolomide Resistant) Glioblastoma
Radiation Therapy Oncology Group·Early Phase 1·ClinicalTrials.gov·drugCompleted
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Brain and Central Nervous System Tumors
Drug/Device/Intervention
temozolomide 60 mg x 21 days
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Radiation Therapy Oncology Group
Location
La Jolla,Los Angeles,'Ewa Beach,Honolulu,Honolulu,Honolulu,Chicago,Prairie Village,Lexington,Louisville,Pascagoula,Reno,Lebanon,New Brunswick,Rochester,Rochester,Portland, United States of America
Timeline & enrollment
Phase
Early Phase 1
Start date
Jul 01, 2010
End date
Dec 01, 2016
Enrollment
257 participants
Primary outcome

Phase 1: Maximum Tolerated Dose (MTD),Phase II: 6-month Progression-free Survival (PFS) Rate for Patients With Measurable Disease After Surgery

Summary

RATIONALE: Veliparib may stop the growth of tumor cells by blocking some of the enzymes
 needed for cell growth. Drugs used in chemotherapy, such as temozolomide. work in different
 ways to stop the growth of tumor cells, either by killing the cells or by stopping them from
 dividing. Giving veliparib together with temozolomide may kill more tumor cells.
 
 PURPOSE: This randomized phase I/II trial is studying the side effects and best dose of
 giving veliparib together with temozolomide and to see how well it works in treating patients
 with recurrent glioblastoma.

ICD-10 classifications
Malignant neoplasm: Overlapping lesion of brain and other parts of central nervous systemMalignant neoplasm: Central nervous system, unspecifiedBenign neoplasm of brain and other parts of central nervous systemMalignant neoplasm of brainSecondary malignant neoplasm of other and unspecified parts of nervous system
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT01026493
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT01026493 through Pure Global AI's free database. This Early Phase 1 trial is sponsored by Radiation Therapy Oncology Group and is currently Completed. The study focuses on Brain and Central Nervous System Tumors. Target enrollment is 257 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.